{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:24:41Z","timestamp":1793834681767,"version":"4.6.1"},"reference-count":36,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,2,1]]},"DOI":"10.1080\/03007995.2023.2277850","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:27:20Z","timestamp":1702290440000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician\u2019s choice of treatment in patients with triple-class exposed\/refractory multiple myeloma"],"prefix":"10.1080","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6366-9178","authenticated-orcid":false,"given":"Isha","family":"Mol","sequence":"first","affiliation":[{"name":"Cytel Inc","place":["Rotterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Hu","sequence":"additional","affiliation":[{"name":"Cytel Inc","place":["Rotterdam, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Groton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-598X","authenticated-orcid":false,"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Tadworth, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Aydin","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["Istanbul, Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3332-0180","authenticated-orcid":false,"given":"Alex","family":"Schepart","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141"},{"key":"e_1_3_6_3_1","unstructured":"Cancer Research UK. Multiple myeloma; 2020. Available from: https:\/\/www.cancerresearchuk.org\/about-cancer\/myeloma\/about."},{"issue":"2","key":"e_1_3_6_4_1","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et\u00a0al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.","journal-title":"Hemasphere"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_3_6_7_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). Multiple myeloma version 3.2023. [cited 2022 Nov 23]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.307"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_3_6_14_1","unstructured":"European Medicines Agency. Summary of product characteristics: nexpovio. Amsterdam. [cited 2021 May 27]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexpovio."},{"key":"e_1_3_6_15_1","unstructured":"European Medicines Agency. Summary of Product Characteristics: Abecma. Amsterdam. [cited 2021 August 25]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abecma."},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184088"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_6_18_1","unstructured":"Liu A. J&J shelves Carvykti\u2019s UK launch amid manufacturing shortfalls. FiercePharma. 2023."},{"key":"e_1_3_6_19_1","unstructured":"AerzteZeitung. Janssen f\u00fchrt neues Blutkrebsmittel nicht in Deutschland ein. AerzteZeitung.de. 2022."},{"key":"e_1_3_6_20_1","unstructured":"Food and Drug Administration. FDA grants accelerated approval to elranatamab-BCMM for multiple myeloma. 2023. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma."},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2236303"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02551-9"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-05058-5"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1511"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0271-1"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_6_29_1","first-page":"82","volume-title":"NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE","author":"Phillippo D","year":"2016","unstructured":"Phillippo D, Ades T, Dias S, et\u00a0al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. University of Sheffield, NICE Decision Support Unit; 2016. p. 82."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02480-7"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0045"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101374"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040590"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8031"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27023"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2277850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:38:50Z","timestamp":1775047130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2277850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"alternative-id":["10.1080\/03007995.2023.2277850"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2277850","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}